Ozempic Alternatives: 7 Verified Research Peptides Compared 2026

Searches for Ozempic alternatives often conflate three distinct categories: other approved GLP-1 agents, investigational multi-receptor peptides in late-stage trials, and unrelated peptides that act on entirely different metabolic pathways. This comparison sorts seven research-relevant compounds by receptor target, molecular weight, half-life, and current development status as of 2026.

Tirzepatide (Eli Lilly, Mounjaro/Zepbound) is the only dual incretin agonist with FDA approval for both T2D and chronic weight management. Molecular weight 4813 Da, 39 amino acids, once weekly subcutaneous, half-life ~117 hours. SURMOUNT-1 produced -22.5% mean weight loss at 15 mg over 72 weeks, and SURMOUNT-5 showed superiority over semaglutide. Approved 2022 (T2D) and 2023 (obesity).

Liraglutide (Novo Nordisk, Victoza/Saxenda) is the predecessor of semaglutide. Molecular weight 3751 Da, daily subcutaneous, half-life ~13 hours. SCALE Obesity and Prediabetes trial reported approximately -8% weight loss at 56 weeks. Liraglutide lost composition-of-matter exclusivity in 2023 and authorized generics began launching in 2024, making it the most accessible GLP-1 in 2026 by price.

Cagrilintide is a once-weekly amylin receptor agonist developed by Novo Nordisk. Molecular weight 3984 Da, 32 amino acids, half-life ~159 hours. Phase 2 monotherapy showed approximately -10.8% weight loss. The principal development program is the fixed-dose combination CagriSema (cagrilintide + semaglutide), with REDEFINE Phase 3 results in 2024-2025 showing combined weight loss in the high teens. Cagrilintide is investigational in 2026.

Retatrutide (Eli Lilly) is a triple agonist of GIP, GLP-1, and glucagon receptors. Phase 2 reported approximately -24.2% weight loss at 12 mg over 48 weeks, the largest mean weight loss reported for any once-weekly peptide. Phase 3 TRIUMPH program is ongoing in 2026. Retatrutide is investigational and not FDA-approved as of 2026. Research-grade material exists for in vitro work and reference characterization only.

Survodutide (Boehringer Ingelheim/Zealand Pharma) is a dual GLP-1/glucagon receptor agonist. Phase 2 in obesity showed approximately -19% weight loss at 46 weeks. The compound has additional Phase 2/3 programs for MASH (metabolic dysfunction-associated steatohepatitis). Survodutide is investigational in 2026.

Orforglipron (Eli Lilly) is a non-peptide small-molecule GLP-1 receptor agonist taken orally without food restrictions. The ATTAIN-1 and ACHIEVE-1 Phase 3 trials reported HbA1c reductions of -1.5 to -1.6% and weight loss in the -7 to -10% range. Orforglipron received FDA approval in 2025 for adults with T2D and is positioned as the first scalable, no-cold-chain oral GLP-1. Daily oral, half-life ~30 hours.

AOD-9604 is a 16-amino-acid fragment of human growth hormone (residues 177-191) plus a tyrosine, marketed in research literature as a lipolytic agent acting via beta-3 adrenergic and lipase pathways rather than GLP-1. Molecular weight ~1817 Da. Human trials in obesity from the 2000s did not show meaningful weight loss versus placebo, and the FDA has not approved AOD-9604 for any indication. It is widely sold as a research peptide, but its evidence tier is materially weaker than the GLP-1 class.

• Tirzepatide: GIP+GLP-1, 4813 Da, ~117h, FDA-approved (T2D, obesity), Tier 1 evidence
• Semaglutide (reference): GLP-1, 4114 Da, ~165h, FDA-approved (T2D, obesity, CV), Tier 1
• Liraglutide: GLP-1, 3751 Da, ~13h, FDA-approved (T2D, obesity), Tier 1
• Cagrilintide: amylin, 3984 Da, ~159h, Phase 3 (combo), Tier 2
• Retatrutide: GIP+GLP-1+glucagon, 4731 Da, ~108h, Phase 3, Tier 2
• Survodutide: GLP-1+glucagon, ~5023 Da, ~134h, Phase 2/3, Tier 2
• Orforglipron: GLP-1 (small molecule), ~566 Da, ~30h, FDA-approved 2025 (T2D), Tier 1
• AOD-9604: lipase/lipolytic, ~1817 Da, short, no approval, Tier 4 (weak human evidence)

Tier 1 means at least one large randomized controlled trial with hard endpoints supporting the indication, plus regulatory approval. Tier 2 means Phase 2 or Phase 3 efficacy data without final approval. Tier 3 means small mechanism-of-action human trials. Tier 4 means animal data, mechanistic plausibility, or older human studies that did not show effect. The literal Ozempic alternatives in 2026 are tirzepatide, liraglutide, and orforglipron. Everything else is investigational or weaker.

• Read more: Ozempic vs Wegovy: Same Drug, Different Indications Explained 2026 → https://www.chemverify.com/learn/ozempic-vs-wegovy-same-drug-different-2026
• Read more: Survodutide: Complete Research Guide & Chemical Profile → https://www.chemverify.com/learn/survodutide-research-guide-chemical-profile
• Read more: Mounjaro vs Ozempic vs Wegovy: 2026 Complete Comparison Guide → https://www.chemverify.com/learn/mounjaro-vs-ozempic-vs-wegovy-2026-comparison
• Read more: Retatrutide: Complete Research Guide & Chemical Profile → https://www.chemverify.com/learn/retatrutide-research-guide-chemical-profile